[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minimally-invasive-coronary-revascularization-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minimally-invasive-coronary-revascularization-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100632536","minimally-invasive-coronary-artery-bypass-supported-by-cangrelor-100632536",false,"NCT07514962","Minimally Invasive Coronary Artery Bypass Supported by Cangrelor","MINOTAUR","Inclusion Criteria for the historical control arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n\nInclusion criteria for the prospective arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n* Signed informed consent\n\nExclusion criteria for the historical control arm\n\n* Administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding\n\nExclusion criteria for the prospective arm\n\n* Unconsciousness\n* Known hypersensitivity to study drug (cangrelor)\n* Recent administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.\n\nThe study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.\n\nStudy Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?\n\nHypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.\n\nThis study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.",[24,25,26],"Coronary Artery Disease","Antiplatelet Therapy","Minimally Invasive Coronary Revascularization Surgery",[28,29,24,30,31,32,33,34,35,36],"Minimally Invasive Direct Coronary Artery Bypass","MIDCAB Surgery","Cangrelor","Perioperative Antiplatelet Therapy","Platelet Function Monitoring","Bridging Therapy","Cardiac Surgery","Intraoperative Antiplatelet Management","Bleeding Risk","RECRUITING","2026-04-13",{"date":40,"type":41},"2026-04-14","ACTUAL",{"date":43,"type":41},"2024-05-12",{"date":45,"type":20},"2028-01-01",{"name":47,"class":48},"Cardiocentro Ticino","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100617093","multivessel-minimally-invasive-coronary-bypass-grafting-as-hybrid-revascularization-versus-conventional-off-pump-coronary-artery-bypass-grafting-100617093","NCT07314138","Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting","MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'","MICRA-HYBRID","Inclusion Criteria:\n\n* Patients with three-vessel disease (either angiographic stenoses \\>70% or a fractional flow reserve value ≤0.80)\n* Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery\n\nExclusion Criteria:\n\nA potential participant who meets any of the following criteria will be excluded from participation in this study:\n\n* Age \\\u003C 18 or \\> 85 years\n* Chronic total occlusion of the RCA\n* In-stent RCA restenosis\n* RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation.\n* Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization.\n* Acute cardiac ischemia necessitating immediate intervention.\n* EF \\\u003C 30 %\n* eGFR \\\u003C 30 ml\u002Fmin\n* Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery\n* Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer.\n* Hemodynamically significant left subclavian stenosis\n* Severe chest wall deformities\n* History of pericarditis\n* Body mass index \\> 40 Kg\u002Fm2.",true,"85 Years",{"count":61,"type":20},250,"INTERVENTIONAL",[64],"NA","The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day \"textbook\" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.",[67,68,26,69],"Coronary Artery Disease (CAD)","Bypass, Cardiopulmonary","Off-pump Coronary Artery Bypass",[71,72,73,74,75],"minimally invasive coronary surgery","percutaneous coronary intervention","off-pump coronary artery bypass grafting","hybrid coronary revascularization","heart surgery","NOT_YET_RECRUITING","2025-12-23",{"date":79,"type":41},"2026-01-02",{"date":81,"type":20},"2026-04-01",{"date":83,"type":20},"2034-05-01",{"name":85,"class":48},"Catharina Ziekenhuis Eindhoven",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":62,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":49},"100592077","impact-of-total-coronary-revascularization-via-left-anterior-thoracotomy-tcrat-vs-robotic-assisted-harvesting-of-lima-itcrats-100592077","NCT06988735","Impact of Total Coronary Revascularization Via Left Anterior Thoracotomy (TCRAT) vs. Robotic-Assisted Harvesting of LIMA (ITcrats)","Impact of Total Coronary Revascularization Via Left Anterior Thoracotomy (TCRAT) vs. Robotic-Assisted Harvesting of Left Internal Thoracic Artery on Hospital Stay (ITcrats)","ITcrats","Inclusion Criteria:\n\n* Scheduled for any type of elective minimally invasive coronary revascularization surgery.\n* Using CPB.\n* General anesthesia is provided in an endotracheally intubated patient\n\nExclusion Criteria:\n\n* Planned for coronary revascularization surgery without CPB;\n* Planned for a combined coronary revascularization surgery and a valve or intra-cardiac surgery;\n* LVEF less than 35%;\n* Preoperative cardiogenic shock;\n* Pregnancy;\n* Scheduled for re-do or emergency surgery;\n* Consent for another interventional study during anesthesia;\n* No written informed consent;\n* Preoperative need for mechanical circulatory support;\n* Preoperative need for invasive ventilatory support;",{"count":96,"type":20},182,[64],"The two types of total coronary revascularization via left anterior thoracotomy (TCRAT) might have their potential benefits and disadvantages. The proposed randomized clinical trial here will compare 'RA-TCRAT' with 'Nonrobotic TCRAT' procedures concerning effects on hospital stays, overall healthcare costs, safety, and feasibility. If the two TCRAT procedures are comparably effective and safe, the 'Nonrobotic TCRAT' procedure is probably preferred as it seems easier to use. However, if the 'Nonrobotic TCRAT' procedure is less effective and less safe than the \"robotic TCRAT,' that procedure should be preferred.",[26,100],"Elective Surgery",[102,103,104,105,106,107,108],"minimally invasive coronary revascularization surgery","robotic-assisted coronary artery bypass graft (RA-CABG)","major adverse cardiovascular events (MACCE)","major adverse cerebrovascular events","cardiopulmonary bypass (CPB)","hospital stays","costs and charges","2025-06-01",{"date":111,"type":41},"2025-06-04",{"date":113,"type":20},"2025-07",{"date":115,"type":20},"2027-08",{"name":117,"class":48},"Mohamed R El Tahan"]